Title: Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
Authors: Sitbon, O ×
McLaughlin, V V
Badesch, D B
Barst, R J
Black, C
Galiè, N
Humbert, M
Rainisio, M
Rubin, L J
Simonneau, G #
Contributors: Delcroix, Marion
Issue Date: Dec-2005
Publisher: British Medical Association
Series Title: Thorax vol:60 issue:12 pages:1025-1030
Abstract: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a life saving treatment.
ISSN: 0040-6376
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Pneumology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science